Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and Dexamethasone in Relapsed/Refractory Hodgkin Lymphoma
NCT00090909Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jun 2003
- Primary completion
- Mar 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin and dexamethasone in Hodgkin lymphoma (HL), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Response Rate and Maximum Response. Started Jun 2003; status: completed.
02
Drugs
gemcitabinecisplatindexamethasone
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00090909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090909.